Table of Contents
MAPLE GROVE, Minn. — Upsher-Smith has debuted its enhanced Promise of Support Program – a patient-centered program designed to offer patients, caregivers, and healthcare providers in the rare disease community comprehensive support throughout the treatment journey. This program is the cornerstone of Upsher-Smith’s dedication to the rare disease community.
The program ensures timely and reliable access to medications through customized services such as quick start and bridge supply programs. Through its partnership with specialty pharmacy, PANTHERx Rare, Upsher-Smith commits to providing a best-in-class experience for patients requiring rare disease medications, responding with urgency, and maintaining clear, open communication. It also includes copay assistance for eligible patients to help lessen the financial burden on patients and their families.
“Upsher-Smith’s Promise of Support Program embodies our longstanding commitment, now in its seventh year, to those impacted by rare diseases,” said Jim Maahs, vice president, specialty & rare disease. “By reducing the complexities of the treatment journey, we hope to offer peace of mind to patients, families, and caregivers to focus on what truly matters – their health and well-being. Upsher-Smith is dedicated to understanding the unique needs of rare disease communities and providing value-added services that ease access to critical medications.”
Upsher-Smith’s rare disease portfolio continues to grow with the addition of high-quality medications that match or exceed the level of service provided by innovator brands. To learn more about the Upsher-Smith Promise of Support Program for the VIGADRONE family of products, visit VIGADRONE.com, and to stay updated on TORPENZ™ (everolimus) Tablets, slated for availability mid-2024, visit www.torpenz.com/availability.
